Recent News for VRNA - Verona Pharma plc

Date Title
Jul 11 The Daily Biotech Pulse: Neurocrine's Parkinson's Drug Accepted For Review, Sunesis Offering, No Headaches For Biohaven's Migraine Drug
Jun 28 The Daily Biotech Pulse: Chiasma To Join R3K Index, EU Rejects Amgen's Osteoporosis Drug Application, Karuna IPO
Jun 25 Verona Pharma Strengthens its Clinical Team Ahead of Phase 3 Development of Ensifentrine
Jun 7 Verona Pharma (VRNA) Presents At Jefferies 2019 Healthcare Conference - Slideshow
Jun 4 Verona Pharma begins mid-stage study of RPL554 for COPD
Jun 4 Verona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPD
May 30 Verona Pharma to Present at Jefferies 2019 Global Healthcare Conference
May 20 Verona Pharma (VRNA) Presents At American Thoracic Society International Conference - Slideshow
May 20 Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at American Thoracic Society 2019 International Conference
May 13 Verona Pharma plc (VRNA) CEO Jan-Anders Karlsson on Q1 2019 Results - Earnings Call Transcript
May 7 Result of AGM
May 7 Verona Pharma reports Q1 results
May 7 Verona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 Trials
May 7 Verona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019
May 3 Key events next week - healthcare
May 2 Verona Pharma to Present Clinical Trial Data of Ensifentrine for COPD Maintenance Treatment at American Thoracic Society 2019 International Conference
May 1 Verona Pharma plc ("Verona" or the "Company") Appointment of Nominated Adviser and UK Broker
May 1 Verona Pharma to Announce Financial Results for First Quarter Ended March 31, 2019 and Provide Clinical Development Update
Apr 25 Verona Pharma to Host Investor & Analyst R&D Forum in London on May 8, 2019
Apr 9 Verona Pharma nabs additional patent in Europe
Apr 9 Verona Pharma Granted Key EU Patent Related to Late-stage COPD Clinical Candidate Ensifentrine
Apr 4 Grant of Options and RSUs and PDMR Dealings
Mar 26 Verona Pharma to Present at H.C. Wainwright Global Life Sciences Conference
Mar 22 2018 Annual Report and Accounts and Notice of AGM 
Mar 21 Dr. Martin Edwards Joins Verona Pharma as Non-Executive Director
Back to the Main VRNA Page...